Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma (PREDATOR)

NCT03697655 is registered in ClinicalTrials.gov with Polish Myeloma Consortium as lead sponsor.

NCT NCT03697655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03697655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma (PREDATOR)
Lead sponsor
Polish Myeloma Consortium
Phase
Phase 2
Overall status
Unknown status
Start date
December 10, 2018
Completion date
July 31, 2024
Enrollment
274 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma